Never Discontinued (n = 51) | Discontinueda (n = 42) | All Patients (N = 93) | |
---|---|---|---|
Patients available for eGFR analysisb, n | 39 | 24 | 63 |
eGFR prior to first dose of eculizumab in parent study, mL/min/1.73 m2 | |||
Mean (SD) | 30.9 (26.9) | 29.6 (29.1) | 30.4 (27.5) |
Median (range) | 24.0 (8.4, 128.3) | 12.0 (10.0, 105.5) | 22.1 (8.4, 128.3) |
eGFR at time of discontinuationc, mL/min/1.73 m2 | |||
Mean (SD) | – | 92.4 (38.6) | – |
Median (range) | – | 92.3 (34.2, 181.5) | – |
eGFR at last follow-up, mL/min/1.73 m2 | |||
Mean (SD) | 65.2 (33.1) | 85.9 (31.8) | 73.1 (33.9) |
Median (range) | 59.5 (14.8, 152.2) | 75.6 (40.0, 153.5) | 65.7 (14.8, 153.5) |
Patients on dialysis prior to first dose of eculizumab in parent study, n/N (%) | 18/51 (35.3) | 17/35 (48.6) | 35/86 (40.7) |
Patients on dialysis at last follow-up, n/N (%) | 2/51 (3.9) | 5/35 (14.3) | 7/86 (8.1) |